Phytomedics, Inc. Announces Appointment Of Pharmaceutical Industry Veteran Dr. Mark W. Pierce, MD, PhD. To Its Board Of Directors

JAMESBURG, N.J., Nov. 21 /PRNewswire/ -- Phytomedics Inc., a biopharmaceutical company merging health care and plant biotechnology to discover, develop and manufacture novel botanical therapeutics, announces the appointment of Dr. Mark W. Pierce, MD, PhD, to its board of directors.

"We are very pleased to have a pharmaceutical executive of Dr. Pierce's caliber join the Phytomedics board of directors," said Dr Bertold Fridlender, President and CEO of Phytomedics. "With his breadth of experience in research and clinical therapeutic development within the pharmaceutical industry, he is an extremely valuable addition to the Phytomedics team."

Dr. Pierce has spent a distinguished 25 year career in various capacities across the global pharmaceutical industry. Most recently he has served as Senior Vice President, Pfizer Global Research and Development, where he had responsibility for worldwide clinical research as well the Neuroscience / Oncology Therapeutic Area. He has also held senior level clinical development positions at both Abbott Laboratories and the Warner-Lambert Company.

"I look forward to serving on the Phytomedics board of directors," said Dr. Pierce. "The company has a fascinating array of commercial opportunities stemming from its botanical therapeutic platform. In addition, it has a very unique approach to ethical drug development that shows promise in bringing novel drugs to market faster and less expensively, and this is a very attractive attribute to potential partners. I look forward to contributing to Phytomedics continuing future success as a director."

A core area of Phytomedics pharmaceutical program are botanical drugs, as recently defined by the U.S. FDA (http://www.fda.gov/cder/Offices/ODE_V_BRT/botanicalDrug.htm). Phytomedics sees this as a unique pharmaceutical niche that allows for the development of heterogenous plant derived products as ethical drugs in the U.S., and do it for reduced costs and time frames in comparison to new chemical entities or biologics, while retaining strong drug market exclusivity.

About Phytomedics Inc.

Phytomedics Inc. (http://www.phytomedics.com) uses a broad and innovative proprietary technology platform to discover, develop and manufacture novel, multi-component and multi-functional botanical therapeutics. Through state-of- the-art, proprietary approaches, Phytomedics' botanical therapeutics program reconnects plants and human health at a new level of technological sophistication. The Company has produced a pipeline of lead compounds, several of which are in clinical development, some as far as Phase II. Founded by Professor Ilya Raskin, Ph.D., Phytomedics Inc. conducts most of its R&D at the Biotech Center of Rutgers University.

Phytomedics Inc.

CONTACT: Ira S. Pastor, Vice President, Business Development ofPhytomedics Inc., +1-609-655-0715, or fax, +1-609-655-0552, orpastor@phytomedics.com

Back to news